CARDIATEAM

Cardiomyopathy in type 2 diabetes mellitus
CARDIATEAM logo

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 13
Grant agreement number
821508

Type of Action: 
RIA (Research and Innovation Action)

Contributions
IMI Funding
6 700 000
EFPIA in kind
6 000 000
Other
182 500
Total Cost
12 882 500

Summary

Diabetic patients are 2.5 times more likely to develop heart failure than people without diabetes. In many patients, the diabetes causes a type of heart dysfunction called cardiomyopathy, which is characterised by functional and structural abnormalities in the heart. Currently, the underlying causes of diabetic cardiomyopathy remain unknown, and there are no effective treatments. The CARDIATEAM project aims to determine how distinct diabetic cardiomyopathy is from other forms of heart failure, and the extent to which type 2 diabetes contributes to its development and progression. The team will recruit 1 600 people with a range of cardiometabolic disorders, including people with diabetes, and follow them for 3 years. By studying this group in detail over time, the team hopes to be able to deliver biological markers that would indicate which diabetes patients are at greatest risk of developing diabetic cardiomyopathy, as well as a more detailed understanding of the disease. Ultimately, the project results will make it easier to provide people with diabetes with more personalised approaches to managing their condition and preventing diabetic cardiomyopathy.

Participants Show participants on map

EFPIA companies
  • Bayer Aktiengesellschaft, Leverkusen, Germany
  • Eli Lilly and Company Limited, Basingstoke, United Kingdom
  • Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France
Universities, research organisations, public bodies, non-profit groups
  • Assistance Publique - Hopitaux De Paris, Paris, France
  • Consorcio Centro De Investigacion Biomedica En Red M.P., Madrid, Spain
  • Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt GMBH, Neuherberg, Germany
  • Hospices Civils De Lyon, lyon, France
  • Institut National De La Sante Et De La Recherche Medicale, Paris, France
  • Katholieke Universiteit Leuven, Leuven, Belgium
  • Luxembourg Institute Of Health, Luxembourg, Luxembourg
  • SIB Institut Suisse De Bioinformatique, CH-660-0733998-3, Genève, Switzerland
  • Stichting Netherlands Heart Institute, Utrecht, Netherlands
  • The Queen'S University Of Belfast, Belfast, United Kingdom
  • Universita Degli Studi Di Torino, Turin, Italy
  • Universitaetsklinikum Aachen, Aachen, Germany
  • Universite D'Aix Marseille, Marseille, France
  • University Of Dundee, Dundee, United Kingdom
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Metabrain Research, Maison-Alfort, France
  • Opale, Paris, France
Patient organisations
  • Universitatsklinikum Heidelberg, Heidelberg, Germany
Third parties
  • Academisch Ziekenhuis Groningen, Groningen, Netherlands
  • Centre D'Etude Et De Recherche Multimodal Et Pluridisciplinaire En Imagerie Du Vivant Gie, Bron Cedex, France
  • Clinical Trial Center Maastricht, Maastricht, Netherlands
  • Fundacio Hospital Universitari Vall D'Hebron - Institut De Recerca, Barcelona, Spain
  • Fundacio Privada Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau, Barcelona, Spain
  • Fundacion Para La Investigacion Biomedica Del Hospital Gregorio Maranon, Madrid, Spain
  • Fundacion Para La Investigacion Biomedica Del Hospital Universitario Ramon Y Cajal, Madrid, Spain
  • Stichting Vumc, Amsterdam, Netherlands
  • Universitair Medisch Centrum Utrecht, Utrecht, Netherlands
Non EFPIA companies
  • Inserm Transfert SA, Paris, France

CONTACT

Project coordinator
Geneviève DERUMEAUX
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
genevieve.derumeaux[at]inserm.fr